Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK3 | Q16288 | 8/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 9/20 | 0.47 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 6/20 | 0.43 |
| ▸ | ABL1 | P00519 | 4/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943088 | 0.87 | SRC (0.55) | BRAFABL1MAP3K7MAP4K2KIT | |
| SCHEMBL21943684 | 0.83 | KDR (0.51) | BRAFKDRKIT | |
| SCHEMBL21942989 | 0.83 | DDR2 (0.50) | NTRK3NTRK1NTRK2DDR2BRAF | |
| SCHEMBL22024548 | 0.82 | DDR2 (0.56) | NTRK3NTRK1NTRK2DDR2BRAF | |
| SCHEMBL21943090 | 0.81 | KIT (0.55) | BRAFABL1MAP3K7MAP4K2KIT | |
| SCHEMBL21943019 | 0.81 | KIT (0.53) | BRAFDDR1ABL1MAP3K7MAP4K2 | |
| SCHEMBL22024709 | 0.80 | DDR2 (0.52) | NTRK3NTRK1NTRK2DDR2BRAF | |
| SCHEMBL21943529 | 0.80 | KIT (0.52) | BRAFDDR1ABL1MAP3K7MAP4K2 | |
| SCHEMBL21943462 | 0.80 | KIT (0.52) | BRAFDDR1ABL1MAP3K7MAP4K2 | |
| SCHEMBL21943387 | 0.80 | KDR (0.55) | NTRK3NTRK1NTRK2DDR2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | XIAMEN UNIVERSITY (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123162-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CYP4A11, CYP2D6, CYP3A43 | NTRK3 1266/4885NTRK1 2046/4885NTRK2 2755/4885 |
| US-11319322-B2 | Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof | CYP4A11, CYP2D6, CYP3A43 | NTRK3 1266/4885NTRK1 2046/4885NTRK2 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.